Loading clinical trials...
Loading clinical trials...
A 12 Week Treatment, Open-label, Multicenter Study to Investigate the Efficacy and Safety of Valsartan 160-320 mg With Regard to Effects on Lipid Subfractions in Hypertensive Patients With Metabolic Syndrome
Conditions
Interventions
Valsartan
Locations
2
Germany
Investigative Centers, Germany
Novartis
Basel, Switzerland
Start Date
November 1, 2005
Primary Completion Date
June 1, 2007
Completion Date
June 1, 2007
Last Updated
February 24, 2017
NCT02417740
NCT07073820
NCT07480265
NCT06876233
NCT07237750
NCT06062394
Lead Sponsor
Novartis
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions